Publications by authors named "Sultan Linjawi"

Claim this Profile
C
Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes.
Stewart Harris, Martin J Abrahamson, Antonio Ceriello, Guillaume Charpentier, Marc Evans, Sultan Linjawi

Drugs· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES.
Ildiko Lingvay, Yehuda Handelsman, Sultan Linjawi, Tina Vilsbøll, Natalie Halladin

Endocr Pract· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes.
Andreas Liebl, Viswanathan Mohan, Wenying Yang, Krzysztof Strojek, Sultan Linjawi

Drugs R D· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 32-Week Randomized Comparison of Stepwise Insulin Intensification of Biphasic Insulin Aspart (BIAsp 30) Versus Basal-Bolus Therapy in Insulin-Naïve Patients with Type 2 Diabetes.
Sultan Linjawi, Byung-Wan Lee, Ömür Tabak, Susanna Lövdahl, Shanti Werther

Diabetes Ther· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial.
Sultan Linjawi, Bruce W Bode, Louis B Chaykin, Jean-Pierre Courrèges, Yehuda Handelsman

Diabetes Ther· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
Sultan Linjawi, Radhakrishna Sothiratnam, Ramazan Sari, Henning Andersen, Line Conradsen Hiort

Prim Care Diabetes· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test.
Jens J Holst, John B Buse, Helena W Rodbard, Sultan Linjawi, Vincent C Woo

J Diabetes Sci Technol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
Stephen C L Gough, Bruce Bode, Vincent Woo, Helena W Rodbard, Sultan Linjawi

Lancet Diabetes Endocrinol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis